Abstract
Background People with HIV (PWH) often have a suboptimal response to vaccines, raising concerns about the efficacy of coronavirus disease 2019 (COVID-19) vaccines in this population. We aimed to evaluate the humoral immune response to the B.1 lineage and Omicron variant in PWH following COVID-19 vaccination.
Methods We conducted a prospective study on 19 PWH who received a two-dose series of the COVID-19 mRNA vaccine and a booster six months later. Participants without HIV infection were included as a healthy control (HC) group. The humoral response to the COVID-19 vaccine (anti-SARS-CoV-2 S IgG levels and ability to block ACE2-S interaction) against both the original B.1 lineage and the Omicron variant was measured by immunoassays.
Results The humoral response in PWH was very strong (GMFR >8) after the second dose and strong (GMFR >4) after the booster dose for both the B.1 lineage and the Omicron variant. We found similar humoral responses to the B.1 lineage and Omicron variant between PWH and HC groups after the second and booster doses (q-value >0.05). The COVID-19 vaccine generated a significantly weaker humoral response against the Omicron variant compared to the B.1 lineage in both groups (q-value <0.05). However, this response improved after the booster dose, although the inhibition of ACE2-S interaction remained weaker in PWH.
Conclusions PWH generated a strong humoral response to the COVID-19 vaccine against both the B.1 lineage and the Omicron variant, similar to individuals without HIV infection. However, our data suggest the need for booster doses to improve immunogenicity and update COVID-19 vaccines for new variants like Omicron.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by The Centro de Investigacion Biomedica en Red (CIBER) de Enfermedades Infecciosas (CB21/13/00044).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the Hospital Universitario Infanta Leonor (HUIL) gave ethical approval for this work (Ref.: 030-21)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
